← Forte Biosciences, Inc. (FBRX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Forte Biosciences, Inc. (FBRX)
Pharmaceutical Preparations · market cap $248M · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-02-28 (est.)
Phase 2
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Forte Biosciences (FBRX) is a small-cap (~$510M market cap, 16 employees) pharmaceutical company with two Phase 2 assets: FB102 for Celiac Disease and FB-401 for Atopic Dermatitis. The company has $58.2M cash (~9.3 months runway) and no revenue, with a key Phase 2 readout for FB102 expected around February 2027.
The catalyst path
- 2027-02-28 (est.)Phase 2 · FB102imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| FB102 | Phase 2 | Celiac Disease |
| FB-401 | Phase 2 | Atopic Dermatitis |
Price & technical context
3-month
+283.6%
6-month
+163.4%
12-month
+546.4%
52-wk range
$10.30–$76.99
vs 50-day MA
+64.5%
vs 200-day MA
+151.8%
Realized vol
114.5%
Max drawdown
-81.3%
Daily closes through 2026-08-28. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for FBRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.